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  Calcium phosphates have long been used as synthetic 
bone grafts. Recent studies have shown that the modu-
lation of composition and textural properties, such as 
nano-, micro- and macro-porosity, is a powerful strategy 
to control and synchronize material resorption and bone 
formation.
  Biomimetic calcium phosphates, which closely mimic 
the composition and structure of bone mineral, can be 
produced using low-temperature processing routes, and 
offer the possibility to modulate the material properties to 
a larger extent than conventional high temperature sinter-
ing processes.
  Advanced technologies open up new possibilities in the 
design of bioceramics for bone regeneration; 3D-printing 
technologies, in combination with the development of 
hybrid materials with enhanced mechanical properties, 
supported by finite element modelling tools, are expected 
to enable the design and fabrication of mechanically com-
petent patient-specific bone grafts.
  The association of ions, drugs and cells allows leverag-
ing of the osteogenic potential of bioceramic scaffolds in 
compromised clinical situations, where the intrinsic bone 
regeneration potential is impaired.
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Bone as a living tissue: the bone healing 
process
Bone composition: the role of bone mineral
Bone is a metabolically active tissue, containing several 
types of cells in a unique extracellular matrix. A distinctive 
feature of the extracellular matrix of bone is its composite 
nature, as it is made of a network of collagen fibres 
reinforced with a mineral phase, i.e. calcium phosphate 
(CaP) crystals. The mineral phase, hydroxyapatite (HA) 
represents approximately 65% of the weight of the bone 
tissue. However, the properties of bone are not explained 
simply by its composition, but also by its complex struc-
ture. In fact, from a mechanical point of view, the proper-
ties of collagen and HA are poor compared with some 
engineering materials. Bone tissue mechanical properties 
are remarkable owing to the way both components are 
arranged and structured together. Bone formation follows 
a bottom-up approach, making it a hierarchically organ-
ized nanocomposite.1 This provides bone with a unique 
combination of properties such as high strength and low 
Young’s modulus, resulting in high toughness.
However, the mineral phase of bone cannot be regarded 
only as the reinforcing phase of a composite material. In 
addition to its mechanical function bone fulfils a series of 
metabolic and physiological functions. Here also the min-
eral phase plays a very relevant role. The apatite nanocrys-
tals function as a chemical reservoir of both calcium (Ca) 
and phosphorus (P) in the body. In the case that levels of 
calcium or phosphorus are too low in body fluids, osteo-
clasts can resorb bone to resolve ion deficiency quickly.2 Bio-
logical apatite is significantly different in composition from 
stoichiometric HA (Ca10(PO4)6(OH)2). In addition to being 
calcium-deficient, it contains large amounts of carbonate 
(up to 8% of its weight) and acidic phosphate groups, and it 
accommodates many other ions in its structure like sodium 
(Na), magnesium (Mg), potassium (K), strontium (Sr), fluor 
(F) and chloride (Cl), in addition to structural water. The 
presence of these ionic substitutions and lattice vacancies, 
together with the nanometric size of the biological apatite, 
results in a high reactivity, enabling its capacity to maintain 
the ionic balance in the body fluids.3,4
Bone formation and remodelling
When addressing the challenge of designing bioceramics 
for bone regeneration it is important to keep in mind the 
process of bone formation, healing and remodelling.
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Bone is a dynamic tissue that is constantly being remod-
elled.4 Our entire skeleton is renewed every five to ten 
years. Old bone is resorbed by the action of osteoclasts 
and new bone is laid down by osteoblasts. This is a respon-
sive process: bone is able to shift the balance between 
osteoblastic and osteoclastic activity according to external 
stimuli.5 Indeed, biomechanical stimuli can foster the 
activity of osteoblasts, thus increasing bone mass under 
increased loads (mechanotransduction). Alternatively, 
when the load-bearing requirements are reduced, osteo-
clastic activity is promoted, leading to bone resorption. In 
other circumstances, the triggering signal in this equilib-
rium is chemical rather than mechanical, and osteoclasts 
are deployed to resorb bone in order to release calcium or 
phosphate to the body fluid that is necessary for specific 
metabolic reasons.
As previously mentioned, osteoblasts are responsible 
for the synthesis, deposition and mineralization of bone 
extracellular matrix. They not only produce the organic 
molecules, i.e. collagen type I, glycosaminoglycans, trans-
forming growth factors or bone morphogenetic proteins 
(BMPs), but also control the mineralization of collagen. 
After fulfilling their secretory activity, osteoblasts undergo 
either apoptosis (about 80%) or terminal differentiation to 
osteocytes (about 20%).
Osteocytes are quiescent osteoblasts embedded in the 
mineralized matrix. They communicate with each other by 
cytoplasmic processes within interconnecting channels 
(canaliculi) in the matrix. They are crucial for maintaining 
the osseous matrix, participate in extracellular exchanges 
and are involved in the mechanotransduction process.6
Osteoclasts are derived from the monocyte- macrophage 
lineage and are responsible for bone resorption.7,8 They 
are able to degrade both the inorganic phase of bone by 
releasing acidic species, i.e. protons, and the organic phase 
through specific enzymes that digest the organic compo-
nents. Monocyte-macrophage lineage cells play an impor-
tant role in the triggering of bone repair processes; it is 
believed that the fusion-differentiation of monocytes in 
osteoclasts and subsequent osteoclastic activity is induced 
through chemokines – chemotaxis events on osteopro-
genitors cells.9 Understanding and controlling the response 
of osteoclasts to bioceramics by tuning chemical and struc-
tural features is of paramount importance for bone tissue 
regeneration.10,11
Bone grafting
As described in the previous section, bone has the capac-
ity to regenerate in specific circumstances. However, this 
capacity is not unlimited; it is restricted to small bone 
defects. There is no biological mechanism for large-scale 
repair of bone. This is the case, for example, in large bone 
defects caused by open trauma or by resection of 
tumours. In other cases, the bone regeneration fails due 
to other factors such as in the case of fracture nonunions; 
or it is necessary to increase the amount of bone prior or 
posterior to the placement of implants. In these clinical 
situations, the use of materials acting as a bridge to sup-
port and, if possible, stimulate bone growth is needed. 
According to Giannoudis et al,12 more than 2.2 million 
bone grafting procedures are performed annually in the 
world. Clinically, the most common strategy is the use of 
autografts. While biologically ideal, they present impor-
tant drawbacks such as the need for a second surgical 
intervention, the limited amount that is harvestable and 
sometimes residual pain over time at the harvesting site. 
Grafts from bone banks or other animal species are still 
subject to risks, such as immunological reactions or dis-
ease transmission.13
The development of synthetic materials emerges as a 
distinct strategy, allowing the aforementioned limitations 
to be overcome. Although they currently only account for 
around 20% of the market for bone regeneration materi-
als, their use is increasing. Synthetic biomaterials are 
obtained from chemical reagents by controlled synthetic 
processes, allowing the tuning of their properties in order 
to fit the specific requirements of different clinical situa-
tions,14 even in compromised scenarios as, for instance, in 
osteoporotic patients.15 In this latter situation, where the 
bone remodelling mechanisms are impaired, the osteo-
genic potency of CaP bone grafts can be fostered by com-
bining them with drugs, growth factors or gene delivery 
strategies, as well as with cell therapies.15 There is a large 
variety of biomaterials for bone regeneration on the mar-
ket (e.g. granules, blocks, putties, cements, etc.), which 
will be discussed in the following sections.
Synthetic bone grafts: state of the art
Main compositions and historical evolution
A biomaterial is a material designed to interact with bio-
logical systems for either a therapeutic or diagnostic 
medical purpose. Different biomaterials have been pro-
posed as synthetic bone graft substitutes, ranging from 
metals, like titanium or tantalum, to polymers like poly-
lactides or hydrogel-based materials.16 However, the 
most extensively used are bioceramics, and among them, 
calcium orthophosphates due to their similarity to the 
mineral phase of bone.17-19 There are several calcium 
orthophosphate compounds, as displayed in Table 1, 
which can be obtained either by precipitation at room or 
body temperature in aqueous solutions (the first six 
compounds), or by solid state reactions at high tempera-
tures (the last four compounds). Interestingly, HA is the 
only CaP that can be obtained both by precipitation in 
aqueous systems at low temperature (precipitated HA) 
and by solid state reaction (sintered HA).
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In general, the lower the calcium/phosphorus ratio, the 
more acidic and soluble in water. The exception is tetra-
calcium phosphate (TTCP), which in spite of having the 
highest calcium/phosphorus ratio is more soluble than HA 
and beta tricalcium phosphate (β-TCP).
The first documented application of a CaP to stimulate 
bone regeneration dates from 1920. Albee20 reported faster 
healing in surgically-induced gaps in dog’s bones when ali-
quots of ‘triple calcium phosphate’ were injected into the 
defect.20 However, it was not until the 1970s that the first 
CaP synthetic bone grafts were introduced to the market. 
Their use spread in the 1990s due to increasing concerns 
about disease transmission by xeno- and allografts, associ-
ated with the social awareness caused by some diseases like 
bovine encephalitis and acquired immune deficiency syn-
drome. Since then, important improvements have been 
achieved, both on the technical side and in the biological 
performance, as summarized in Figure 1.
Sintered bioceramics
Historically, the first bioceramics used as synthetic bone 
grafts were HA and β-TCP, both obtained at high tempera-
ture by a sintering process. Special attention was paid to 
HA, due to its similarity with the mineral phase of bone. The 
Table 1. Main calcium phosphates used as biomaterials13,14,17
Calcium/phosphorus ratio Name Symbol/mineral name Chemical formula Solubility*
0.5 Monocalcium phosphate monohydrate MCPM Ca(H2PO4)2·H2O ~18
1.0 Dicalcium phosphate dihydrate DCPD/brushite CaHPO4·2H2O ~0.088
1.0 Dicalcium phosphate anhydrous DCPA/monetite CaHPO4 ~0.048
1.3-2.5 Amorphous calcium phosphate ACP (Ca,X)x(PO4,Y)y·nH2O
X = Mg2+, Zn2+, Sn2+,Al3+;
Y = (CO3)2-, (P2O7)4-
N.A.
1.33 Octacalcium phosphate OCP Ca8H2(PO4)6·5H2O ~0.0081
1.5-1.67 Precipitated hydroxyapatite† PHA, CDHA Ca10-X(HPO4)X(PO4)6-X(OH)2-X
0⩽x<1
~0.0094
1.5 α-Tricalcium phosphate α-TCP α-Ca3(PO4)2 ~0.0025
1.5 β-Tricalcium phosphate β-TCP β-Ca3(PO4)2 ~0.0005
1.67 Sintered hydroxyapatite SHA/hydroxyapatite Ca10(PO4)6(OH)2 ~0.0003
2.0 Tetracalcium phosphate TTCP/hilgenstockite Ca4(PO4)2O ~0.0007
*solubility in g/L in water at 25 °C
†when x > 0 one talks about calcium deficient hydroxyapatite, CDHA. It is common to have x = 1, which leads to the composition Ca9(HPO4)(PO4)5(OH)
Fig. 1 Historical overview of relevant milestones in the research and development (R&D) of calcium phosphate (CaP) biomaterials 
(HA, hydroxyapatite; β-TCP, beta tricalcium phosphate).
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initial idea of developing dental implants or osteosynthesis 
devices made of HA required the optimization of the 
mechanical properties to ensure stability. Therefore, much 
effort was devoted to producing high temperature sintered 
HA with low porosity and high crystallinity to minimize 
excessive reactivity. However, it was soon evident that sin-
tered HA, in addition to being too brittle to be reliable for 
load-bearing applications, was non- biodegradable and 
hardly bioactive. Osteoclasts are unable to rapidly dissolve 
the much more stable, stoichiometric and highly crystal-
line sintered HA. In an attempt to increase the degradation 
rate, in the late 1980s Daculsi et  al21 introduced an 
approach based on the combination of HA with the more 
soluble ceramic phase β-TCP: the biphasic CaPs (BCP). 
Since then, BCPs with different relative phase proportions 
and thus different resorbabilities have been extensively 
used in the form of blocks and granules.22
CaP cements (CPCs)
The introduction of CPCs in the early 1980s by LeGeros23 
and Brown and Chow24 represented a breakthrough in 
CaP research. It provided clinicians with mouldable and 
even injectable pastes that were able to harden within the 
body. The initial formulation was based on TTCP and dical-
cium phosphate (DCP) (Table 1), which reacted to set into 
HA. Later on, other formulations were developed and apa-
titic cements were proposed based on other compounds 
like alpha TCP (α-TCP), and also cements that produce 
other final phases like brushite (DCP dihydrate, DCPD) or 
monetite (DCP anhydrous, DCPA).25,26 The wide range of 
formulations allows users to adapt its properties to specific 
clinical needs and requirements for different degrees of 
resorbability. The hardening of the cement is based on a 
dissolution and precipitation reaction and the formation of 
a porous network of micrometric/nanometric CaP crystals 
(Fig. 2).27 Unlike in acrylic bone cements, widely used in 
orthopaedic surgery for arthroplasty fixation and vertebro-
plasty, the setting reaction in CPC is not exothermic,28 and 
therefore allows the incorporation of drugs and biologi-
cally active molecules, like antibiotics or growth factors, 
which can provide additional functionalities or increase the 
osteogenic capacity.29
Different issues remain to be improved in CPC, such as 
mechanical properties – to more closely mimic those of 
natural bone. Modification with soluble polymers30 and 
reinforcement with polymer and ceramic fibres31,32 repre-
sent a step forward in this direction. Another aspect that 
has been the subject of extensive research is the adjust-
ment of porosity as a strategy to enhance biological perfor-
mance.33 Although self-setting CPCs are intrinsically 
porous, with porosities in the nano/micron range, they still 
require interconnected macropores > 100 µm to allow tis-
sue ingrowth and neovascularization and to ensure a fast 
healing response. This has been accomplished using differ-
ent strategies, such as the introduction of biocompatible 
surfactants to the formulation, which allows the produc-
tion of self-setting apatitic foams34,35 and the development 
of self-setting inks that can be used in additive manufactur-
ing techniques, such as 3D microextrusion.36,37
Synthesis of ion-substituted apatites
One of the specific features of biological apatites is the 
presence of a number of foreign ions which, in addition 
to modifying the structure and reactivity of the mineral, 
play an important metabolic role.38 On this basis, HA sub-
stituted with biologically relevant ions has been synthe-
sized and proposed as an attractive biomaterial for bone 
grafting, prompting a large number of studies.39 Atomic 
substitutions in synthetic apatites can be produced by 
small changes in the composition of the reactants in the 
Fig. 2 Calcium phosphate cements: processing and microstructure.
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synthesis. Traditionally the most studied ions were carbon-
ates, due to their abundant presence in bone mineral, and 
fluoride in particular for dental applications as it was associ-
ated with the stabilization of the apatite phase in enamel 
(which proved to be an effective prevention strategy for 
tooth decay). More recently, other ions have attracted a 
great deal of attention due to their specific biological effects. 
This has fostered not only the use of ion substituted HA, but 
also that of silicate and phosphate glasses, as matrices for 
the controlled delivery of ions.40,41 For example, strontium 
has been used for the treatment of osteoporosis, based on 
its stimulation of osteoblastic differentiation and inhibition 
of osteoclastogenesis;42,43 silicon has been incorporated 
into CaPs taking advantage of their osteogenic properties 
due to its role in bone development;44 and silver has been 
used due to its antimicrobial activity.45
Osteoinductive ceramics
The development of bioceramics with intrinsic osteoin-
ductive properties is one of the most important achieve-
ments in the field of synthetic CaPs in past decades. A 
range of CaPs have revealed osteoinductive properties, in 
the sense that they have the ability to trigger the differen-
tiation of non-differentiated cells towards the osteogenic 
lineage. This mechanism leads to bone formation, even in 
the absence of exogenous BMPs, and is also associated 
with a higher bone healing capacity when implanted 
orthotopically, compared with non-osteoinductive ceram-
ics.46 It has also been reported that osteoinductive ceram-
ics perform similarly to autologous bone graft and rBMP2 
(recombinant bone morphogenetic protein 2) in repairing 
critical-size bone defects.47 Although the mechanism 
underlying bone induction is still not fully understood, it 
seems clear that it is the result of the combination of sev-
eral parameters rather than of a single one. Chemical 
composition, macropore size and geometry, microporos-
ity, surface microstructure and specific surface area have 
been shown to play key roles.19,46 One of the most plausi-
ble hypotheses behind osteoinduction combines the nat-
ural ability of CaP to bind BMPs with the presence of 
concavities within the scaffold that helps the retaining and 
concentrating of BMPs and ions in the vicinity of the scaf-
fold, creating a favourable niche for the differentiation of 
mesenchymal stem cells (MSCs).48-51 The identification of 
these properties and the mechanisms involved in osteoin-
duction will definitely lead to the design of synthetic bone 
grafts with higher osteogenic potential, initiating solu-
tions to compromised clinical situations. Recently, it has 
been shown that the nanostructured nature of biomimetic 
HA leads to an accelerated osteoinduction when com-
pared with microstructured sintered ceramics with analo-
gous composition.52
Sintered versus biomimetic CaPs
In recent years attention has been focused on the enhance-
ment of the biological properties of synthetic bone grafts. 
In order to design synthetic bone grafts able to perform as 
well as or even outperform autografts, it is necessary to 
establish the appropriate interactions between the graft, 
the osseous cells and the extracellular matrix. The final 
goal is to obtain materials that can be recognized and pro-
cessed by osteoclasts in a similar way to the natural bone 
extracellular matrix. In other words, biomaterials are 
sought that can enter the physiological bone remodelling 
cycle. In this sense, it seems counterintuitive to continue 
relying on the traditional high temperature processing 
strategies that are so far from the mild processes involved 
in bone formation.18 It is important to highlight the fact 
that the synthetic process determines not only the com-
position of a material, but also the final properties that this 
material will have, such as solubility, morphology, poros-
ity, crystallite size and specific surface area. In the case of 
ceramics, the high-temperature treatment (sintering pro-
cess) generates a final structure consisting of large crystals 
with low specific surface area and a low nano-/micro-
porosity and, therefore, low reactivity.
Considerable research efforts have been devoted to bio-
mimetic processing methods of CaP as they result in mate-
rials with composition, morphology, crystallinity and 
solubility much closer to the biological apatite.53,54 The 
processing techniques associated with CPCs allow fulfil-
ment of this objective. They result in fabricated scaffolds, 
pre-set granules or macroporous blocks using mild con-
solidation methods through low-temperature dissolution–
precipitation reactions that mimic the biomineralization 
phenomena (Fig. 2).53 The differences between the 
Fig. 3 Scanning electron micrographs of different microstructures 
of calcium phosphates. Top: Biomimetic calcium-deficient 
hydroxyapatite (CDHA) obtained by a self-setting reaction of alpha 
TCP, using a coarse powder (CDHAC) or a fine powder (CDHAF). 
Bottom: Sintered calcium phosphates, beta tricalcium phosphate 
(β-TCP) and sintered hydroxyapatite (SHA). Scale bar: 500 nm. 
Adapted from Diez Escudero et al,55 with permission.
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microstructures of sintered and biomimetic CaPs can be 
appreciated in the scanning electron microscope images 
displayed in Figure 3.55
Architecture and porosity
Following the principles of tissue engineering, porosity 
has become a key feature in the design of biomaterials for 
bone regeneration. There is increasing evidence that some 
crucial aspects regarding the clinical success of bioceram-
ics, such as the rate of resorption and the extent of angio-
genesis and tissue colonization, depend not only on the 
intrinsic properties of the material but also on the amount, 
size and shape of the pores it contains.56,57 Thus, while 
porosity can be a limitation for the use of these materials 
in high-load bearing applications, it is vital for other appli-
cations. Porosity is sought to enhance a material’s resorb-
ability and the extent of bioactivity by increasing the 
surface area available for reaction.58
Three pore size regions are often distinguished when 
dealing with biomaterials or scaffolds for tissue engineer-
ing: macropores (pores > 100 µm), micropores (in the 
range of 0.1 µm to 10 µm) and nanopores (< 0.1 µm). The 
role of macroporosity in an ideal bone graft is to guide 
and support tissue ingrowth within the material so that 
colonization and angiogenesis can take place along with 
the progressive bioresorption of the scaffold. When using 
granulated materials, the space in between individual 
granules defines a macroporous network even if there is 
no mechanical continuity in the material. Alternatively, 
the use of macroporous blocks or foams is proposed, as a 
means to promote tissue ingrowth.
But it is not just large pores that are important; the con-
trol of the micro- and nanostructure of a ceramic, and 
therefore the micro- and nanoporosity, has been shown to 
play a very relevant a role in material resorption and bone 
formation. Small-size pores, of micrometric or nanometric 
size, have a critical effect on the biological response by 
influencing protein adsorption, cell adhesion and the 
permeability of the biomaterial to the physiological fluids. 
It is well known, for example, that CaPs with a micropo-
rous structure have a higher osteogenic capacity and even 
greater osteoinduction capacity than their non-micropo-
rous analogues.46 This trend is even clearer in nanostruc-
tured ceramics, both in vitro and in vivo.52,59
In contrast to high-temperature ceramics, presenting 
pores in the micrometric range, the low-temperature 
routes allow fabrication of CaP nanostructured materials 
(Fig. 3), extending the pore size range to much smaller 
sizes and thus increasing substantially the specific surface 
area and reactivity of the materials. The modulation of the 
specific surface area and the porosity at a multiscale level 
(nano-, micro- and macro-porosity) has become a power-
ful tool that allows fine-tuning of the degradation of 
CaPs.55
Open challenges in the design of high 
performance synthetic bone grafts
In the previous sections, an overview of the important 
developments in CaP research over 40 years was pro-
vided. Significant advances made in the last few decades 
coupled with recent technological developments ensure a 
bright future for these materials. In this last section we 
have spotted some promising topics, which may be of 
interest in the coming years.
Enhancement of mechanical properties
CaP ceramics have poor mechanical properties and are 
brittle in nature. Therefore, they are not suitable for load-
bearing applications. Although there have been several 
attempts to improve the mechanical properties of CaP 
ceramics by combining them with polymers,60 as of today 
no biodegradable composites have been obtained with a 
combination of strength, ductility and toughness close to 
that of cortical bone. In this sense, one of the most prom-
ising lines of research is the one based on a biomimetic 
approach, applying bottom-up strategies and trying to 
reproduce hierarchical structures at multiple length scales 
(from the molecular to the macroscopic scale), to have 
hybrid materials displaying the desired combinations of 
properties (strength, toughness, ductility, density, etc). 
This approach, based on the combination of architectural 
gradients, is constantly used in nature to build natural 
structural materials with exceptional properties.1
Bioceramics as drug delivery systems: bio-inorganics and 
biological molecules
The design of synthetic bone grafts combining both oste-
ogenic and antimicrobial properties would represent a 
major breakthrough. Recent studies have shown that low 
temperature biomimetic CaPs offer an excellent platform 
to incorporate antibiotics, as they offer the possibility to 
Fig. 4 Images of macroporous scaffolds obtained with 
biomimetic hydroxyapatite: a) injectable self-setting 
hydroxyapatite foam; b) structure obtained by 3D micro-
extrusion of a self-setting hydroxyapatite ink.
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control the release kinetics by adapting the textural prop-
erties of the biomaterial, preserving intact the activity of 
the drug.61,62 Similarly, other active principles can be 
incorporated, like anti-inflammatories or anti-cancer 
drugs, or even growth factors, like BMPs, which can 
enhance the bone graft’s osteogenic potential.63 How-
ever, some challenges remain, such as the control of the 
release kinetics over an appropriate time period, monitor-
ing the release in vivo or ensuring a reproducible perfor-
mance in different locations, clinical situations and patient 
specificities.
In addition to the delivery of antibiotics or other bio-
molecules, bioceramics can be used as vehicles for the 
local delivery of active ions, able to trigger specific biologi-
cal responses.41,64,65 Thus, ions such as copper, strontium, 
zinc, cobalt, silicon and boron have the potential to stimu-
late osteogenesis and angiogenesis while copper, zinc 
and silver have also demonstrated anti-inflammatory and 
antibiotic capabilities. Important advantages of this 
approach are those associated with lower cost and better 
stability.66
Injectable porous biomaterials
Injectable materials have many advantages in surgical 
practice.67 The possibility of having an injectable biomate-
rial combining both multiscale porosity and the capacity 
to harden in situ would bring significant benefits to clinical 
practices, such as the compatibility with minimally- 
invasive surgical techniques, the geometrical fit to the 
defect thanks to the moldability of the material, superior 
reactivity and drug delivery capability through the pres-
ence of nano-/micropores and the possibility to be colo-
nized by tissues due to the presence of a macropore 
network. Recent studies show the feasibility of designing 
such materials68,69 (Fig. 4). Moreover, the possibility of 
using these materials as drug delivery matrices is very 
attractive, as recent studies have shown that, in addition 
to enhancing osteoconduction and material resorption, 
the multiscale porosity presented by these materials ena-
bles tuning the local delivery of drugs.62
Bioceramics and cell-based therapies
Bioceramics can also play a significant role in bone tissue 
engineering. Since bioceramics were introduced in the 
1990s, they are being increasingly used as a bone grafting 
strategy,70 using hybrid constructs that combine bone 
marrow cells or MSCs with synthetic scaffolds, typically 
made from porous ceramics and molecular signals71 
(Fig. 5). This strategy is particularly suited to complex skel-
etal injuries lacking sufficient osteogenic potential. 
Although significant progress has been made in this field in 
recent years and several clinical studies are under way both 
in Europe and the United States,76 a better understanding 
of the role of each of the components and the interactions 
amongst them remains to be reached. In  particular, the 
development of scaffolds that are able not only to support 
cell attachment and growth, but to also provide the ade-
quate temporary niche to the cells and instruct them in the 
right direction, may represent a significant step forward for 
the efficacy of this therapeutic approach.77 One aspect to 
be aware of is the myriad of possibilities that can be consid-
ered in the cell therapy field and the lack of sufficient 
reported data allowing for the correlation of results. Thus, 
the creation of international databases on clinical trials to 
help spread information becomes an urgent need for both 
researchers and surgeons.78
Still another challenging aspect associated with tissue 
engineering strategies is obtaining regulatory approval of 
products to conduct clinical studies. Indeed, tissue engi-
neering approaches combining materials with cells are 
Fig. 5 Bone tissue engineering requires ex vivo expansion of 
marrow-derived skeletal stem cells and their attachment to 3D 
scaffolds, such as calcium phosphate ceramic particles. This 
hybrid construct can be transplanted into segmental defects 
and will subsequently regenerate an appropriate 3D structure in 
vivo. Adapted from Bianco et al,70 with permission.
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considered biological devices and the regulatory path 
imposed by agencies both in Europe and United States is 
far more strict than for non-biological products.79 This 
also applies to scaffolds combined with biological entities 
if their proposed mechanism of action is considered to be 
biological. Thus, any translation of a discovery in the labo-
ratory into a tissue engineering product not only faces 
technical challenges but also needs to guarantee regula-
tory approval in order to safely and effectively bring the 
product to the market.
Bioceramics for personalized implants
The latest 3D-printing technologies are particularly suited 
for the design of personalized bone grafts36,80,81 as they 
provide an accurate control of the geometry. The design of 
the implant shape, based on x-ray computed tomography 
(CT) data, ensures a perfect fit between the graft and the 
anatomical defect. Significant advances have been reached 
in the printing of CaP structures using technologies such 
as powder bed fusion (a laser beam melts and fuses mate-
rial powder together),82 binder jetting (a liquid binder is 
dispensed to join powder particles),83 fused deposition 
modelling (a temperature-controlled head extrudes a ther-
moplastic polymeric-ceramic composite followed by a 
quick solidification),84 solvent evaporation-assisted print-
ing (a concentrated polymer-ceramic solution is extruded 
following rapid solvent evaporation)85 and micro- extrusion 
(extrusion of a thixotropic ink to form self-supportive struc-
tures), the latter being the most widely employed (Fig. 4).86 
Typical ink formulations, which consist of a suspension of 
ceramic powders, like HA or β-TCP, using polymeric bind-
ers, require a sintering step to consolidate the printed 
green body.86 More recently self-hardening CaP inks have 
been developed based on reactive CaPs like α-TCP, which 
allow skipping of the sintering step and, since they harden 
at a low temperature, this making them extremely versatile 
for the incorporation of biological molecules.87,88 The pos-
sibility of working at low temperatures broadens the appli-
cability of this technique to potentially have in-hospital 
patient specific bone graft manufacturing facilities, allow-
ing surgeons to obtain ready to use bone grafts at low 
temperature in a few hours, revolutionizing the treatment 
of emergency cases and changing the way surgical plan-
ning is done for non-urgent cases.89
One important aspect associated with 3D printing is the 
possibility of adjusting the geometry and microstructure of 
the scaffold to tune its final mechanical properties.90 To 
this end, finite element analysis is an extremely powerful 
tool to better understand and predict the mechanical 
properties of the scaffold. Furthermore, the use of in silico 
models that combine biomechanical requirements with 
cell fate predictions can further aid in the design of func-
tional patient-specific 3D scaffolds at reduced cost.91
Conclusions
Bone is a self-repairing material. However, in some com-
promised clinical situations the self-regeneration mecha-
nism fails, and it is necessary to induce bone formation 
beyond the capacity of the host tissue. The development of 
biomimetic synthetic materials with composition and 
structural features closer to natural bone stands as a prom-
ising strategy to improve the synchronization between 
bone formation and material resorption. Ideal bone grafts 
should tightly balance resorption and new bone deposi-
tion across different conditions imposed by the patient 
age, gender and social habits (sport, addictions), as well as 
the specific loads at the implantation site. New technolo-
gies allow great versatility and a more precise control in 
the design of scaffolds. However, the issue is now to decide 
which architecture and features the graft should have to 
spur regeneration in each particular situation. Understand-
ing the biological mechanism of interaction between graft 
at the bony site is crucial to progress in the development of 
high performance, patient-specific bioceramics.
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